ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Baxter, Mayo, And VPD Launch Vitesse

by Lisa M. Jarvis
June 8, 2015 | APPEARED IN VOLUME 93, ISSUE 23

The venture arm of Baxter has teamed with Velocity Pharmaceutical Development (VPD) and the Mayo Clinic to launch Vitesse Biologics, a collaboration to develop antibody- and protein-based therapeutics. Each partner will play a role in the drug development process. VPD will identify drug targets, pick early-stage molecules, and take on preclinical studies. Mayo will conduct Phase I trials of drug candidates, and Baxter BioScience will contribute manufacturing and commercialization capabilities. Baxter BioScience, which will soon be spun off into a stand-alone company called Baxalta, will have an exclusive option to acquire any product developed by Vitesse after Phase I studies are complete.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment